Figure 2.
Biochemical and cellular assays of mutant sensitivity to imatinib. (A) Kinase assays were performed with escalating doses of imatinib for the isolated wild-type and mutant Abl kinase domain. IC50 values are reported as the concentration of imatinib required to reduce the autophosphorylation signal by 50%. Three independent experiments were averaged. Representative gels are shown. (B) Composite graphs of the biochemical inhibition of kinase domain mutants and the cellular growth inhibition of BaF3 cells expressing Bcr-Abl mutant isoforms. Graphs represent the average of 3 independent experiments. For space considerations, single-letter amino acid codes are used here in place of 3-letter codes.
